Endovascular Treatment of HCC

Background:Hepatic tumors, in particular hepatocellular carcinoma (HCC), present an almost exclusive arterial supply as opposed to the normal parenchyma, which is vascularized by the portal vein. The neo-angiogenesis creates the possibility of releasing high quantities of drugs or radiation directly into the tumor, minimizing systemic effects. Aim and objectives: Aim of the study was to evaluate the response of TACE treatment after 1,6,12 and 24 months comparing EASL criteria and the most recent modified RECIST (mRECIST) criteria and to assess the efficacy and tolerability of DEB-TACE for the treatment of HCC. Conclusion: DEB-TACE is more effective than cTACE in early and intermediate-stage HCC with fewer complications but without statistically significant superiority